Scarica l'app Stockscreener
11.80
0.76%
-0.09
Dopo l'orario di chiusura:
11.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.89
Aprire:
$11.82
Volume 24 ore:
702.86K
Relative Volume:
1.20
Capitalizzazione di mercato:
$586.70M
Reddito:
-
Utile/perdita netta:
$-156.39M
Rapporto P/E:
-3.1978
EPS:
-3.69
Flusso di cassa netto:
$-123.06M
1 W Prestazione:
+2.88%
1M Prestazione:
-9.79%
6M Prestazione:
+17.30%
1 anno Prestazione:
+4.89%
Intervallo 1D:
$11.44
$11.87
Intervallo di 1 settimana:
$11.11
$11.93
Portata 52W:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Nome
Kalvista Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 999-0075
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Confronta KALV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.80 | 570.24M | 0 | -156.39M | -123.06M | -3.69 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-12-18 | Iniziato | BofA Securities | Buy |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-29 | Iniziato | SVB Leerink | Outperform |
| 2019-03-20 | Iniziato | Needham | Buy |
| 2018-10-30 | Iniziato | Jefferies | Buy |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Iniziato | BTIG Research | Buy |
Mostra tutto
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
KalVista Pharmaceuticals to Present at the Jefferies Global Heal - GuruFocus
KalVista Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Jane Street Group LLC - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Position Lessened by D. E. Shaw & Co. Inc. - Defense World
Northern Trust Corp Sells 13,205 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
(KALV) Proactive Strategies - news.stocktradersdaily.com
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings - Business Wire
Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com
(KALV) Investment Analysis - news.stocktradersdaily.com
Tower Research Capital LLC TRC Has $54,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Dimensional Fund Advisors LP Acquires 89,001 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Head-To-Head Comparison: KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of “Buy” by Analysts - Defense World
Wells Fargo & Company MN Has $171,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
MetLife Investment Management LLC Lowers Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-07-2025 11 - marketscreener.com
Analyzing Ratios: KalVista Pharmaceuticals Inc (KALV)’s Financial Story Unveiled - DWinneX
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
JPMorgan Chase & Co. Decreases Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Trading (KALV) With Integrated Risk Controls - news.stocktradersdaily.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 - BioSpace
Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Should investors be concerned about KalVista Pharmaceuticals Inc (KALV)? - uspostnews.com
KalVista Pharmaceuticals Inc [KALV] Shares Jump Approximately 27.74% Over the Year - knoxdaily.com
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference - BioSpace
KalVista Pharmaceuticals Inc (KALV) stock analysis: A comprehensive overview - uspostnews.com
Geode Capital Management LLC Sells 8,632 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Kalvista stock holds $19 target, Market Outperform rating - Investing.com
Kalvista stock holds $19 target, Market Outperform rating By Investing.com - Investing.com India
Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com
(KALV) Trading Report - news.stocktradersdaily.com
Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle
The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter
KalVista: Poised For Rare Disease Transformation - Seeking Alpha
Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News
KalVista licensing deal with Kaken - The Pharma Letter
KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia
KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa
KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology
Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):